ArticleProceedings of the National Academy of Sciences of the United States of America2001
Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 223 citations in OpenAlex.
- Homologous recombination pathway alterations in basal-like breast cancer.Frontiers in oncology · 2026Review
- Androgen receptor-mediated regulation of BRCA1 modulates the antioxidant defense in prostate cancer.The Journal of pathology · 2025Article
- Exploring ID4 as a driver of aggression and a therapeutic target in triple-negative breast cancer.NPJ breast cancer · 2025Article
- Genome-Wide Association Study Reveals Genetic Mechanisms Underlying Intersex and Aproctia in Large White Pigs.Animals : an open access journal from MDPI · 2025Article
- The Critical Role of Inhibitor of Differentiation 4 in Breast Cancer: From Mammary Gland Development to Tumor Progression.Cancer medicine · 2025Review
- Inhibitory effect of miR342 on the progression of triple-negative breast cancer cells in vitro and in the mice model.BioImpacts : BI · 2024Article
- Upregulation of Receptor Tyrosine Kinase Activity and Stemness as Resistance Mechanisms to Akt Inhibitors in Breast Cancer.Cancers · 2022Article
- CDC42 as an epigenetic regulator of ID4 in triple-negative breast tumors.Breast cancer (Tokyo, Japan) · 2022Article
- ID1 and ID4 Are Biomarkers of Tumor Aggressiveness and Poor Outcome in Immunophenotypes of Breast Cancer.Cancers · 2021Article
- Oncogenes in high grade serous adenocarcinoma of the ovary.Genes & cancer · 2020Article
- Ovarian Cancer Risk Variants Are Enriched in Histotype-Specific Enhancers and Disrupt Transcription Factor Binding Sites.American journal of human genetics · 2020Article
- Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer.Breast cancer research : BCR · 2020Article
- Expression and Prognostic Value of Id-4 in Patients with Esophageal Squamous Cell Carcinoma.OncoTargets and therapy · 2020Article
- LncRNA SNHG7 promotes pancreatic cancer proliferation through ID4 by sponging miR-342-3p.Cell & bioscience · 2019Article
- Epigenetic regulation of ID4 in breast cancer: tumor suppressor or oncogene?Clinical epigenetics · 2018Article
- Expression of ID4 protein in breast cancer cells induces reprogramming of tumour-associated macrophages.Breast cancer research : BCR · 2018Article
- Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer.Bioscience reports · 2018Review
- Checkpoint Kinase 1 Expression Predicts Poor Prognosis in Nigerian Breast Cancer Patients.Molecular diagnosis & therapy · 2018Article
- Id4 promotes cell proliferation in hepatocellular carcinoma.Chinese journal of cancer · 2017Article
- Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Review
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Expression of the breast and ovarian cancer susceptibility gene BRCA1 is down-regulated in sporadic breast and ovarian cancer cases. Therefore, the identification of genes involved in the regulation of BRCA1 expression might lead to new insights into the pathogenesis and treatment of these tumors. In the present study, an "inverse genomics" approach based on a randomized ribozyme gene library was applied to identify cellular genes regulating BRCA1 expression. A ribozyme gene library with randomized target recognition sequences was introduced into human ovarian cancer-derived cells stably expressing a selectable marker [enhanced green fluorescence protein (EGFP)] under the control of the BRCA1 promoter. Cells in which BRCA1 expression was upregulated by particular ribozymes were selected through their concomitant increase in EGFP expression. The cellular target gene of one ribozyme was identified to be the dominant negative transcriptional regulator Id4. Modulation of Id4 expression resulted in inversely regulated expression of BRCA1. In addition, increase in Id4 expression was associated with the ability of cells to exhibit anchorage-independent growth, demonstrating the biological relevance of this gene. Our data suggest that Id4 is a crucial gene regulating BRCA1 expression and might therefore be important for the BRCA1 regulatory pathway involved in the pathogenesis of sporadic breast and ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.